



*Just What Women
Want in Healthcare*

FOR IMMEDIATE RELEASE:

**AGILE THERAPEUTICS TO REPORT ON DEVELOPMENT STATUS OF
NEW GENERATION LOW-ESTROGEN DOSE CONTRACEPTIVE
PATCH AT BIO 2007 CONFERENCE**

Princeton, NJ – April 18, 2007 – Dr. Thomas M. Rossi, President and Chief Executive Officer of Agile Therapeutics, Inc., will report on the company's progress in developing a new generation of transdermal contraceptives at the BIO 2007 annual international conference on biotechnology. Agile is an early stage Women's Healthcare company, whose low estrogen dose, seven-day transdermal contraceptive patch is currently in phase 2 clinical development.

The BIO 2007 conference will be held at the Boston Convention and Exhibition Center in Boston, MA on May 6 - May 9th, 2007. Dr. Rossi is scheduled to present at 9:30 am in Room C. Agile Therapeutics is privately held and supported by high-quality health care investors, including ProQuest, a healthcare venture capital firm that is managing over \$875 million; the Hillman Company and its Affiliates, a diversified investment firm active in venture capital investing for over 25 years; TL Ventures, with over \$1.4 billion under management; and PA Early Stage Partners, with more than \$235 million under management.

About Agile Therapeutics

Agile Therapeutics is a privately funded women's health company. The Company's lead product is a low estrogen dose seven-day transdermal contraceptive. This unique patch system delivers a combination of levonorgestrel and ethinyl estradiol. Agile's patch is expected to compete effectively in the \$5 billion worldwide contraceptive market and is currently in Phase II clinical development. The Company is supported by high-quality health care investors, including ProQuest, a healthcare venture capital firm that is managing over \$875 million; the Hillman Company and its Affiliates, a diversified investment firm active in venture capital investing for over 25 years; TL Ventures, with over \$1.4 billion under management; and PA Early Stage Partners, with more than \$235 million under management.

#